For research use only. Not for therapeutic Use.
cyclo(RLsKDK) (TFA) (BK-1361 (TFA)) is a specific inhibitor of metalloproteinase ADAM8 with an IC50 value of 182 nM. cyclo(RLsKDK) (TFA) has potential applications in inflammatory diseases and cancer[1].
cyclo(RLsKDK) (TFA) promotes ADAM8 activation and CD23 shedding with IC50 values of 120 nM and 182 nM, respectively[2].
cyclo(RLsKDK) (TFA) (200 nM; 0-120 h) increases activity of pro-ADAM8[2].
cyclo(RLsKDK) (TFA) (200 nM and 500 nM; 12 h) promotes the growth of Panc1_ctrl and Panc1_A8 cells[2].
cyclo(RLsKDK) (TFA) (500 nM) causes ERK1/2 phosphorylation in Panc1_ctrl and Panc1_A8 cells[2].
cyclo(RLsKDK) (TFA) (10 µg/g; i.p.; once weekly for 4 weeks) significantly reduces tumour load in mice which implant Panc1_ctrl or Panc1_A8 cells. cyclo(RLsKDK) (TFA) improves the survival rate of pancreatic ductal adenocarcinoma (PDAC) mice, reduces soluble ADAM8 (sADAM8) content, pERK1/2 activation, and PDAC metastasis in the liver and lungs of PDAC mice[2].
| Catalog Number | I041335 |
| Synonyms | 2-[(2S,5S,8S,11S,14R,17S)-5,17-bis(4-aminobutyl)-8-[3-(diaminomethylideneamino)propyl]-14-(hydroxymethyl)-11-(2-methylpropyl)-3,6,9,12,15,18-hexaoxo-1,4,7,10,13,16-hexazacyclooctadec-2-yl]acetic acid;2,2,2-trifluoroacetic acid |
| Molecular Formula | C33H58F3N11O11 |
| Purity | ≥95% |
| InChI | InChI=1S/C31H57N11O9.C2HF3O2/c1-17(2)14-21-28(49)42-23(16-43)30(51)39-19(9-4-6-12-33)26(47)41-22(15-24(44)45)29(50)38-18(8-3-5-11-32)25(46)37-20(27(48)40-21)10-7-13-36-31(34)35;3-2(4,5)1(6)7/h17-23,43H,3-16,32-33H2,1-2H3,(H,37,46)(H,38,50)(H,39,51)(H,40,48)(H,41,47)(H,42,49)(H,44,45)(H4,34,35,36);(H,6,7)/t18-,19-,20-,21-,22-,23+;/m0./s1 |
| InChIKey | HZBQMHHFVWPPCH-PJJIVLHTSA-N |
| SMILES | CC(C)CC1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCN=C(N)N)CCCCN)CC(=O)O)CCCCN)CO.C(=O)(C(F)(F)F)O |
| Reference | [1]. Yim V, et al. Synthesis and biological evaluation of analogues of the potent ADAM8 inhibitor cyclo(RLsKDK) for the treatment of inflammatory diseases and cancer metastasis. Bioorg Med Chem. 2016 Sep 15;24(18):4032-4037. [2]. Schlomann U, et al. ADAM8 as a drug target in pancreatic cancer. Nat Commun. 2015 Jan 28;6:6175. |
